{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-25-000018","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2025-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.244991+00:00","generated_at":"2026-05-23T18:58:30.279946+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"iBio reveals preclinical data for IBIO-600 and Activin E antibody combo with semaglutide","bullets":["IBIO-600 NHP study: half-life 40-52 days, potential human half-life up to 130 days; dose-dependent lean mass increase and fat reduction.","Activin E monotherapy in obese mice: ~4% weight loss, 18% fat reduction vs placebo after two weeks.","Activin E + semaglutide combination: 34% total weight loss (9% above semaglutide alone), 72% body fat reduction by DEXA.","Both candidates target obesity and cardiometabolic diseases; IBIO-600 is anti-myostatin, Activin E induces fat-selective weight loss."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-25-000018","json":"https://secwatch.observer/filing/0001420720-25-000018.json","markdown":"https://secwatch.observer/filing/0001420720-25-000018.md","text":"https://secwatch.observer/filing/0001420720-25-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000018/0001420720-25-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000018/ibio-20250408x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T18:58:30.279946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}